Dynogen Presents Results Of Its Positive Phase 2a IBS-c Study With DDP733
May 22nd 2008Drug InformationIrritable-Bowel Syndrome
Dynogen Pharmaceuticals, Inc. announced the presentation of positive results from its Phase 2a clinical trial for DDP733 (pumosetrag) as a treatment for irritable bowel syndrome with constipation (IBS-c) at the Digestive Disease Week 2008 (DDW) scientific meeting.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
